Viracta Therapeutics Investor Relations Material

Viracta Therapeutics Inc. is a precision oncology company focused on developing treatments for virus-associated cancers. The company's leading product candidate, Nana-val, is an all-oral combination therapy comprising its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Beyond Nana-val, Viracta is exploring the "Kick and Kill" approach for other virus-related cancers, aiming to leverage its expertise in oncology to address the needs of patients with virus-associated malignancies globally. Headquartered in Cardiff-by-the-Sea, California, Viracta Therapeutics Inc.'s shares are listed on the Nasdaq.